Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: Role of cathepsin G and protease-activated receptor-4

Inflammatory Bowel Diseases

Volumn 17, Issue 6, 2011, Pages 1409-1414

  Dabek, Marta ^a   Ferrier, Laurent ^a   Annahazi, Anita ^a,b   Bézirard, Valérie ^a   Polizzi, Arnaud ^c   Cartier, Christel ^a   Leveque, Mathilde ^a   Roka, R ^c   Wittmann, Tibor ^c   Theodorou, Vassilia ^d   Bueno, Lionel ^a,c  

^a CNRS   (France)

^b UNIVERSITY OF SZEGED   (Hungary)

^c CEMAGREF   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

cathepsin G; epithelial barrier function; protease activated receptors; ulcerative colitis

Indexed keywords

1 (5 IODO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; CATHEPSIN G; MYELOPEROXIDASE; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN KINASE INHIBITOR; PEPDUCIN P4PAL 10; PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; ENZYME ACTIVITY; FECAL SUPERNATANT; FECES; HUMAN; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPERNATANT; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CATHEPSIN G; CELL MEMBRANE PERMEABILITY; COLITIS; COLITIS, ULCERATIVE; COLON; FECES; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PEROXIDASE; RECEPTORS, THROMBIN; YOUNG ADULT;

EID: 79955826717     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21454     Document Type: Article

References (24)

1. Weber CR, Turner JR., Inflammatory bowel disease: is it really just another break in the wall? Gut. 2007; 56: 6-8. (Pubitemid 46044880)
2. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev. 2001; 53: 245-282. (Pubitemid 32476117)
3. Vergnolle N., Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut. 2005; 54: 867-874. (Pubitemid 40732107)
4. Hollenberg MD, Compton SJ., International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev. 2002; 54: 203-217.
5. Ando S, Otani H, Yagi Y, et al. Protease-activated receptor 4-mediated Ca2+ signaling in mouse lung alveolar epithelial cells. Life Sci. 2007; 81: 794-802. (Pubitemid 47332511)
6. Mule F, Pizzuti R, Capparelli A, et al. Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon. Gut. 2004; 53: 229-234. (Pubitemid 38125510)
7. Dabek M, Ferrier L, Roka R, et al. Luminal cathepsin G and protease-activated receptor 4. A duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol. 2009; 175: 207-214.
8. Sambrano GR, Huang W, Faruqi T, et al. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000; 275: 6819-6823. (Pubitemid 30146221)
9. Sabri A, Alcott SG, Elouardighi H, et al. Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem. 2003; 278: 23944-23954. (Pubitemid 36830223)
10. Houle S, Papez MD, Ferazzini M, et al. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol. 2005; 146: 670-678. (Pubitemid 41573618)
11. Roka R, Rosztoczy A, Leveque M, et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007; 5: 550-555. (Pubitemid 46660764)
12. Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008; 57: 591-599.
13. Cenac N, Chin AC, Garcia-Villar R, et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways. J Physiol. 2004; 558: 913-925. (Pubitemid 39199112)
14. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61-72. (Pubitemid 46044890)
15. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999; 116: 301-309. (Pubitemid 29055352)
16. Clayburgh DR, Shen L, Turner JR., A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004; 84: 282-291. (Pubitemid 41656483)
17. Moriez R, Salvador-Cartier C, Theodorou V, et al. Myosin light chain kinase is involved in lipopolysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol. 2005; 167: 1071-1079. (Pubitemid 41416259)
18. Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982; 78: 206-209. (Pubitemid 12171880)
19. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002; 161: 1903-1915. (Pubitemid 35265547)
20. Vergnolle N, Cellars L, Mencarelli A, et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest. 2004; 114: 1444-1456. (Pubitemid 40385575)
21. Covic L, Misra M, Badar J, et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002; 8: 1161-1165. (Pubitemid 35175972)
22. Nusrat A, Turner JR, Madara JL., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol. 2000; 279: G851-857.
23. Shen L, Black ED, Witkowski ED, et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci. 2006; 119: 2095-2106. (Pubitemid 43904964)
24. Blair SA, Kane SV, Clayburgh DR, et al. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest. 2006; 86: 191-201. (Pubitemid 43117598)